Literature DB >> 2119291

Leukemia inhibitory factor binds with high affinity to preosteoblastic RCT-1 cells and potentiates the retinoic acid induction of alkaline phosphatase.

S B Rodan1, G Wesolowski, D J Hilton, N A Nicola, G A Rodan.   

Abstract

This study examines the effect of leukemia inhibitory factor (LIF) on preosteoblastic rat calvaria (RCT-1) cells, which acquire osteoblastic properties when treated with retinoic acid (RA). LIF potentiated the increase in alkaline phosphatase (AP) activity produced by RA. The LIF effect was time and dose dependent (EC50, approximately 1 pM). The earliest effects on AP activity were detected at 48 h, and maximal effects were observed after 72 h. RA increased AP mRNA about 2-fold at 3 h and 6-fold at 6 and 12 h. LIF further increased AP mRNA to 18-fold at 12 h. After RA treatment AP mRNA returned to control levels at 24 h, but in the presence of LIF, AP mRNA remained elevated at 24 and 72 h of treatment. When given alone, LIF had no effect on either AP activity or mRNA levels. Tumor necrosis factor-alpha and 1,25-dihydroxyvitamin D3 also potentiated the RA induction of AP, and interleukin-6 had a small effect, whereas granulocyte macrophage colony-stimulating factor had no effect. LIF alone had a small inhibitory effect on type 1 collagen mRNA, but did not oppose the stimulatory effect of RA. Consistent with these biological actions, LIF receptors were demonstrated on these cells. [125I]LIF bound to RCT-1 cells at 0 C with an apparent dissociation constant of 20 pM, and it was found that these cells express an average of 300 receptors/cell. Scatchard analyses showed a single class of high affinity binding site. LIF was internalized with an endocytic rate constant for occupied receptors of 0.03 min-1, and the apparent equilibrium dissociation constant at 37 C was 358 pM. These findings suggest that osteoblast precursor cells are among the target cells of LIF.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2119291     DOI: 10.1210/endo-127-4-1602

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  7 in total

1.  Unique ERalpha cistromes control cell type-specific gene regulation.

Authors:  Susan A Krum; Gustavo A Miranda-Carboni; Mathieu Lupien; Jerome Eeckhoute; Jason S Carroll; Myles Brown
Journal:  Mol Endocrinol       Date:  2008-09-25

2.  Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis.

Authors:  M Lotz; T Moats; P M Villiger
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

3.  Detection of receptors for interleukin-6, interleukin-11, leukemia inhibitory factor, oncostatin M, and ciliary neurotrophic factor in bone marrow stromal/osteoblastic cells.

Authors:  T Bellido; N Stahl; T J Farruggella; V Borba; G D Yancopoulos; S C Manolagas
Journal:  J Clin Invest       Date:  1996-01-15       Impact factor: 14.808

4.  Culturing of cells from giant cell tumour of bone on natural and synthetic calcified substrata: the effect of leukaemia inhibitory factor and vitamin D3 on the resorbing activity of osteoclast-like cells.

Authors:  A Soueidan; O I Gan; F Gouin; A Godard; D Heymann; Y Jacques; G Daculsi
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Ciliary Neurotrophic Factor (CNTF) and Its Receptors Signal Regulate Cementoblasts Apoptosis through a Mechanism of ERK1/2 and Caspases Signaling.

Authors:  Jiawen Yong; Sabine Groeger; Julia von Bremen; Sabine Ruf
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

6.  Leukemia inhibitory factor receptor is structurally related to the IL-6 signal transducer, gp130.

Authors:  D P Gearing; C J Thut; T VandeBos; S D Gimpel; P B Delaney; J King; V Price; D Cosman; M P Beckmann
Journal:  EMBO J       Date:  1991-10       Impact factor: 11.598

Review 7.  Stimulation of Osteoclast Formation by Oncostatin M and the Role of WNT16 as a Negative Feedback Regulator.

Authors:  Pedro P C de Souza; Petra Henning; Ulf H Lerner
Journal:  Int J Mol Sci       Date:  2022-03-18       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.